Sanara MedTech (NASDAQ:SMTI) Issues Quarterly Earnings Results, Misses Expectations By $0.03 EPS

Sanara MedTech (NASDAQ:SMTI) posted its earnings results on Tuesday. The company reported ($0.05) earnings per share for the quarter, missing the consensus estimate of ($0.02) by ($0.03), FiscalAI reports. The firm had revenue of $28.14 million during the quarter, compared to analysts’ expectations of $28.95 million. Sanara MedTech had a negative net margin of 29.15% and a positive return on equity of 31.56%.

Sanara MedTech Stock Performance

SMTI stock traded down $0.03 during mid-day trading on Thursday, reaching $34.30. The company had a trading volume of 127,700 shares, compared to its average volume of 100,060. The stock’s 50-day simple moving average is $25.92 and its two-hundred day simple moving average is $21.97. Sanara MedTech has a one year low of $16.05 and a one year high of $35.95. The stock has a market capitalization of $314.15 million, a P/E ratio of -9.55 and a beta of 1.13. The company has a quick ratio of 2.05, a current ratio of 2.28 and a debt-to-equity ratio of 6.59.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the stock. Wall Street Zen cut shares of Sanara MedTech from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 1st. Freedom Capital downgraded Sanara MedTech from a “strong-buy” rating to a “hold” rating in a report on Monday, August 3rd. Zacks Research upgraded shares of Sanara MedTech from a “strong sell” rating to a “hold” rating in a research report on Wednesday, June 10th. HC Wainwright cut shares of Sanara MedTech from a “buy” rating to a “neutral” rating and dropped their price objective for the company from $36.00 to $35.00 in a research note on Thursday, July 30th. Finally, Lake Street Capital cut shares of Sanara MedTech from a “buy” rating to a “hold” rating and set a $35.00 target price for the company. in a research note on Thursday, July 30th. Four investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Reduce” and a consensus price target of $35.00.

Hedge Funds Weigh In On Sanara MedTech

Several institutional investors and hedge funds have recently bought and sold shares of SMTI. Royal Bank of Canada raised its stake in shares of Sanara MedTech by 127.3% in the 4th quarter. Royal Bank of Canada now owns 117,643 shares of the company’s stock valued at $2,747,000 after buying an additional 65,887 shares in the last quarter. Marshall Wace LLP increased its holdings in shares of Sanara MedTech by 144.3% during the second quarter. Marshall Wace LLP now owns 71,511 shares of the company’s stock worth $2,030,000 after buying an additional 42,237 shares in the last quarter. Squarepoint Ops LLC raised its stake in shares of Sanara MedTech by 343.4% in the third quarter. Squarepoint Ops LLC now owns 31,383 shares of the company’s stock valued at $996,000 after acquiring an additional 24,305 shares during the last quarter. Jane Street Group LLC acquired a new stake in Sanara MedTech during the 4th quarter valued at $355,000. Finally, Hsbc Holdings PLC bought a new stake in shares of Sanara MedTech during the second quarter worth $382,000. Hedge funds and other institutional investors own 8.10% of the company’s stock.

About Sanara MedTech

Sanara MedTech is a medical technology company focused on developing and commercializing innovative devices for ear, nose and throat (ENT) healthcare. The company’s core offering centers on minimally invasive sinus dilation systems designed to treat chronic sinusitis and related conditions. These products leverage balloon catheter technology to expand sinus pathways and improve patient outcomes while reducing recovery times. In addition to sinus solutions, the portfolio extends to procedural tools and implants for otology and cranial applications.

With its legacy rooted in the assets of a former Johnson & Johnson business, Sanara MedTech combines decades of research and development in ENT therapies.